AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Citius Pharmaceuticals Inc. Common
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001V1J7S4
0.40▲ 0.03 (8.79%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
0.37
Day's Range
0.37 – 0.41
52-Week Range
0.37 – 1.98
Volume
433.4K
Avg Volume
212.9K
Share Statistics
Shares Outstanding
Employees
23
Exchange
XNAS
Listed
2011-10-18
Share count as of August 13, 2026

Citius Pharmaceuticals Inc. Common (CTXR) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Citius Pharmaceuticals Inc. Common (CTXR)
What is Citius Pharmaceuticals Inc. Common's Market Cap?
Citius Pharmaceuticals Inc. Common's Market Cap is $11.1M, based on as-reported figures from SEC (XBRL) filings.
What is Citius Pharmaceuticals Inc. Common's Enterprise Value?
Citius Pharmaceuticals Inc. Common's Enterprise Value is $294.1M, based on as-reported figures from SEC (XBRL) filings.
What is Citius Pharmaceuticals Inc. Common's Price / Sales?
Citius Pharmaceuticals Inc. Common's Price / Sales is 1.6×, based on as-reported figures from SEC (XBRL) filings.
What is Citius Pharmaceuticals Inc. Common's EV / Revenue?
Citius Pharmaceuticals Inc. Common's EV / Revenue is 41.4×, based on as-reported figures from SEC (XBRL) filings.
What is Citius Pharmaceuticals Inc. Common's EV / EBITDA?
Citius Pharmaceuticals Inc. Common's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Citius Pharmaceuticals Inc. Common's Revenue (TTM)?
Citius Pharmaceuticals Inc. Common's Revenue (TTM) is $7.1M, based on as-reported figures from SEC (XBRL) filings.
What is Citius Pharmaceuticals Inc. Common's Net Income (TTM)?
Citius Pharmaceuticals Inc. Common's Net Income (TTM) is -$58.2M, based on as-reported figures from SEC (XBRL) filings.
What is Citius Pharmaceuticals Inc. Common's EBITDA?
Citius Pharmaceuticals Inc. Common's EBITDA is -$61.4M, based on as-reported figures from SEC (XBRL) filings.
What is Citius Pharmaceuticals Inc. Common's Diluted EPS (TTM)?
Citius Pharmaceuticals Inc. Common's Diluted EPS (TTM) is -2.12, based on as-reported figures from SEC (XBRL) filings.
What is Citius Pharmaceuticals Inc. Common's EBITDA Margin?
Citius Pharmaceuticals Inc. Common's EBITDA Margin is -863.9%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CTXRAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues—
Cost of revenues—
Gross Profit—
% of revenue67.1%80.3%80.0%—
Operating Expenses
Research and development
Amortization of in-process research and development—
General and administrative
Stock-based compensation – general and administrative
Total Operating Expenses
% of revenue852.5%2011.2%308.7%—
Operating Loss
% of revenue-785.4%-1931.0%-228.7%—
Other Income (Expense)
Interest income
Gain on sale of New Jersey net operating losses——
Amortization of deferred financing costs———
Interest expense
Total Other Income (Expense), Net
Loss before Income Taxes
Income tax expense (benefit)
Net Loss
% of revenue-797.9%-1685.9%-238.2%—
Net loss attributable to non-controlling interest
Net loss applicable to common stockholders
Net Loss Per Share - Basic (in Dollars per share)
Net Loss Per Share - Diluted (in Dollars per share)